ABSTRACT: Pleiotropy is the phenomenon by which the same gene can result in multiple phenotypes. Pleiotropic proteins are emerging as important contributors to rare and common disorders. Nevertheless, little is known on the mechanisms underlying pleiotropy and the characteristic of pleiotropic proteins. We analyzed disease-causing proteins reported in UniProt and observed that 12% are pleiotropic (variants in the same protein cause more than one disease). Pleiotropic proteins were enriched in deleterious and rare variants, but not in common variants. Pleiotropic proteins were more likely to be involved in the pathogenesis of neoplasms, neurological, and circulatory diseases and congenital malformations, whereas non-pleiotropic proteins in endocrine and metabolic disorders. Pleiotropic proteins were more essential and had a higher number of interacting partners compared with nonpleiotropic proteins. Significantly more pleiotropic than non-pleiotropic proteins contained at least one intrinsically long disordered region (P < 0.001). Deleterious variants occurring in structurally disordered regions were more commonly found in pleiotropic, rather than nonpleiotropic proteins. In conclusion, pleiotropic proteins are an important contributor to human disease. They represent a biologically different class of proteins compared with non-pleiotropic proteins and a better understanding of their characteristics and genetic variants can greatly aid in the interpretation of genetic studies and drug design.
Introduction
Pleiotropy is the phenomenon by which the same gene can result in multiple phenotypes. The "human disease gene network" developed by Goh et al. (2007) alessia.david09@imperial.ac.uk background between different rare human diseases. Genetic overlap has also been demonstrated between different common disorders [Solovieff et al., 2013; Ligthart et al., 2015] . A recent analysis of genome wide associations studies (GWAS) reported in the GWAS catalogue showed that 16.9% of genes and 4.6% of genetic variants have pleiotropic effects [Sivakumaran et al., 2011] . The widespread presence of pleiotropic genes poses a formidable challenge when analyzing and prioritizing genes and genetic variations responsible for disease. Furthermore, in-depth understanding of pleiotropic proteins and their mechanisms of action is crucial in drug design, in view of the high risk of an off-target effect posed by these proteins. Pleiotropy is a widespread phenomenon across all organisms and is a central feature of evolution [Orr 2000; Wagner et al., 2008; Le Nagard et al., 2011] and the development of complex organisms from a relatively limited set of genes [Hodgkin 1998; Wagner and Zhang 2011] . Although the phenomenon of pleiotropy has been known for over 100 years [Stearns 2010] , the mechanisms by which a single gene can affect multiple traits is still far from being fully understood. Analysis of the properties of pleiotropic protein interaction networks associated with human disease has shown that, similarly to essential proteins, pleiotropic proteins are central in protein-protein interaction networks and have more interactors compared with non-pleiotropic proteins [Zou et al., 2008; Chavali et al., 2010] . At molecular level, several mechanisms have been proposed to explain the pleiotropic effect of a gene and its protein product [Hodgkin 1998 ]. Of these, two appear to prevail: (1) the presence, on the same protein, of different domains with different functions (type 1 pleiotropy) and (2) the utilization of the same protein in multiple biological processes (type 2 pleiotropy) [Wagner and Zhang 2011] .
It has been shown that genetic variants with a pleiotropic effect are more likely to be located in a coding rather than non-coding region [Sivakumaran et al., 2011] . This suggests that analysis of the three-dimensional (3D) structure of pleiotropic proteins and their disease-associated genetic variants may provide insight into the mechanisms underlying pleiotropy. In particular, long structurally disordered regions-protein regions that lack a fixed 3D structureare compelling candidates to explain pleiotropy. The lack of a fixed 3D structure allows the protein amino acid sequence to adopt different 3D conformations, thus allowing for flexibility and interaction with multiple partners in response to different stimuli and the environment [Dunker et al., 2005; Haynes et al., 2006] . Although protein disorder is a well-recognized phenomenon Oldfield and Dunker 2014] , its impact on human disease has just began to be recognized Vacic et al., 2012] . More importantly, its relation to pleiotropy remains to be analyzed.
In this study, we examined the distribution of single amino acid variations (SAVs) in pleiotropic and non-pleiotropic proteins, focusing on the absence of a fixed 3D structure and we analyzed the impact of deleterious SAVs occurring in pleiotropic and nonpleiotropic proteins on human disease. Our results show that: (a) pleiotropic proteins are enriched in disease-causing and rare variants, whereas common variants are more likely to be found in nonpleiotropic proteins; (b) although deleterious variants occur mainly in structurally ordered regions, a deleterious SAV occurring in a disordered region is more common in a pleiotropic rather than non-pleiotropic protein; (c) pleiotropic and non-pleiotropic proteins cause different classes of disorders: neoplasms, neurological, and circulatory diseases and congenital malformations are more likely to be caused by pleiotropic rather than non-pleiotropic proteins, whereas endocrine and metabolic disorders are more likely caused by a non-pleiotropic protein.
Materials and Methods

Construction of the Dataset
We surveyed genotype-phenotype associations reported in UniProt (Humsavar database, release: 2014 08) [Ongoing and future developments at the Universal Protein Resource 2011] for 12,543 proteins. SAVs were divided according to the Humsavar classification in: "disease-causing," when associated with disease and "non-disease-causing" (corresponding to the term "polymorphisms" in Humsavar database) if no association with disease was present. SAVs reported as "unclassified" were not included in the analysis.
Non-disease-causing SAVs were further divided according to their global minor allele frequency (MAF) in: (1) "rare variants" (MAF < 0.01) and (2) "common variants" (MAF ࣙ 0.01). The "common variants" dataset was enriched by adding SAVs with MAF ࣙ 0.01 reported in the EXAC database [Lek et al., 2016] . MAF data for SAVs not listed in EXAC were extracted from Ensembl, using the Biomart data-mining tool [Smedley et al., 2015] .
Each disease associated to the proteins in our dataset was classified according to the International Classification of Diseases tenth revision (ICD-10) [Brämer 1988 ], the standard medical classification of diseases used for clinical and epidemiological purposes by the World Health Organization.
A protein was classified as "pleiotropic" when associated to at least two disorders affecting different physiological systems (e.g., cardiovascular and respiratory systems) or two different conditions belonging to the same physiological system according to the ICD-10 classification (e.g. diabetes type I and obesity both under the "Endocrine and Metabolic" system). A protein was classified as "nonpleiotropic" when associated with only one disorder (i.e., the same identifier in the Online Mendelian Inheritance in Men (OMIM) database).
Since UniProt only reports phenotypes caused by SAVs, diseases caused by truncating variants (i.e. nonsense and frameshift) or canonical splice junction variants are not annotated, thus potentially leading to the erroneous classification of a protein into the non-pleiotropic set. In order to overcome this potential misclassification, we screened proteins in the non-pleiotropic dataset against the morbid map in the OMIM database, which reports proteindisease associations regardless of the type of genetic variant causing them. Proteins reported to be associated with more than one disease in OMIM but not UniProt were excluded from the non-pleiotropic protein dataset but not re-assigned to the pleiotropic dataset. This was done because our aim was to examine the distribution of SAVs on protein structure. The dataset of investigated proteins and variants is available from http://www.sbg.bio.ic.ac.uk/pleiotropydb.
Prediction of Intrinsically Disordered Regions
An "intrinsically disordered region" was defined by the presence of at least 50 consecutive disordered amino acids. Protein disorder was predicted using IUPred [Dosztányi et al., 2005] and the default score 0.5. IUPred predicts disordered regions by calculating the inter-residue interaction energy. Since intrinsically disordered domains can be less than 50 residues long, a threshold of 30 consecutive disordered residues was also used. Moreover, all results were replicated using a second disorder prediction program, Disopred3, which is trained to recognized missing coordinates from high resolution X-ray structures [Ward et al., 2004; Jones and Cozzetto 2015] . IUPred and Disopred3 were chosen among others because they are state of the art [Monastyrskyy et al., 2014] , freely downloadable and sensitive to long disordered regions.
Essential Proteins
Proteins were classified as "essential" or "non-essential" according to whether their mouse ortholog produced a non-viable phenotype. The Mouse Genome Informatics (MGI) database [Bult et al., 2016] was used to retrieve mouse genes that produce a lethal phenotype. A total of 3,440 mouse genes were classified as essential and 3,303 of these genes could be mapped to a human ortholog.
Since some human essential genes have non-essential mouse orthologs [Liao and Zhang 2008] , the Online Gene Essentiality database (OGEE) [Chen et al., 2012] was used to provide alternative assignment of essential genes results. The OGEE database includes data for 1,528 essential human genes obtained from genome-wide experiments [Silva et al., 2008] .
Pathways, Protein Interactors, and Gene Ontology Terms
Pathways data were extracted from the Reactome database [Milacic et al., 2012] . Gene ontology (GO) terms for biological processes, molecular function, and cellular component were retrieved from the GO database [Gene Ontology Consortium 2015] . Protein interactors were retrieved from BioGRID database (version 3.4.131) [Chatr-Aryamontri et al., 2015] .
Statistics
The χ 2 test was used to compare observed and expected frequencies for categorical values. Comparison of medians was performed using the Mann-Whitney-Wilcoxon test. The preference of a SAV to be located in i rather than j was expressed as the odds ratio (OR ij ), calculated as follows:
for x i = number of SAVs in region i/total number of residues in region i.
The P value for the difference between two ORs (OR 1 and OR 2 ) was calculated from the z score:
where δ is the difference between ORs calculated as: δ = |OR 1 | -|OR 2 |, and SE(δ) is the standard error for δ calculated as:
The hypergeometric test was used to calculate the enrichment in GO terms and classes of diseases.
Results were considered statistically significant if P value <0.05. The Benjamini-Hochberg correction [Benjamini and Hochberg 1995] was applied to control for the error rate arising from multiple testing and results were considered significant if a corrected two-sided P value was <0.05.
Results
Protein Dataset
We surveyed genotype-phenotype associations reported in the UniProt database for 12,543 protein-coding genes. 257 proteincoding genes (12% of all proteins associated with at least one diseasecausing SAV reported in UniProt) were classified as "pleiotropic," since they were associated with at least two different disorders affecting the same or different physiological systems. 1,345 protein-coding genes were classified as "non-pleiotropic," since they were associated with only one disease. All the results presented hereafter were generated from the analysis of this dataset comprising 257 pleiotropic proteins.
It is worth noting, that, an additional 155 protein-coding genes (7.3% of disease-causing proteins reported in UniProt) were associated with at least two similar disorders (identified by different OMIM identifiers), which may differ in terms of degree of severity or response to treatment, for example, Crigler-Najjar syndrome type I (MIM# 218800) and type II (MIM# 606785) (a hereditary hyperbilirubinemia caused by genetic variants in UGT1A1). These 155 protein-coding genes did not fulfill our conservative definition of pleiotropy, however they could still be considered pleiotropic when using a less stringent criterion to define pleiotropism. For this reason, these 155 proteins were not included among the 1,345 non-pleiotropic. Moreover, for completeness, we present in Supp Mat the results obtained by including these 155 protein-coding genes in the pleiotropic dataset (total number of pleiotropic protein-coding genes presented in Supp Mat = 412). The dataset of investigated proteins and variants is available from http://www.sbg.bio.ic.ac.uk/pleiotropydb.
Characteristics of Pleiotropic and Non-Pleiotropic Proteins
The median length of proteins encoded by pleiotropic proteincoding genes (pleiotropic proteins) was 570 (range 110-4,967) compared with 509 (range 51-6,885) for proteins encoded by non-pleiotropic protein-coding genes (non-pleiotropic proteins, P < 0.001, Mann-Whitney two-tailed test; data for extended dataset of 412 proteins available in Supp. Table S1 ).
Next, we analyzed the distribution of essential proteins in our dataset by mapping 3,303 human orthologs of mouse essential genes to our protein dataset and found that 59.1% (152) pleiotropic proteins were essential compared with 35.9% (483) non-pleiotropic proteins (P < 0.001, χ 2 test; Fig. 1 , panel A and Supp. Table S2A ). Since not all human essential genes have non-essential mouse orthologs [Liao and Zhang 2008] , we confirmed our results using the OGEE database (20.2% of pleiotropic proteins were classified as essential compared with 10.5% of non-pleiotropic proteins, P < 0.001, χ 2 test; Fig. 1 , panel B and Supp. Table S2B ). We determined the degree of protein-protein interaction (defined as the number of partners a protein interacts with) for each protein in the dataset. The median number of interactors for pleiotropic proteins was 11 (range 0-1,980) compared with 6 (range 0-1,187) for non-pleiotropic proteins (P < 0.001, two-tailed Mann-Whitney test; Fig. 2 and Supp. Table S3 ). These results, which show that pleiotropic proteins are on average longer, more essential, and have more interactors compared with non-pleiotropic proteins, suggest that these two groups comprise of proteins with tendencies to different biological properties.
Differences in the Distribution of Disease-Causing SAVs and Non-Disease-Causing SAVs Across Pleiotropic and Non-Pleiotropic Proteins
We mapped 24,070 disease-causing SAVs and 37,947 additional variants with no known disease association (non-disease-causing SAVs) annotated in Humsavar to our protein dataset (results are presented in Table 1 and Supp. Tables S4A and S4B ). Our final non-redundant dataset contained 15,222 disease-causing SAVs Non-disease-causing SAVs are defined as "common" when MAF ࣙ 0.01 and "rare" when MAF < 0.01. 95% CI, 95% confidence intervals.
(6,100 in pleiotropic and 9,122 in non-pleiotropic proteins) and 4,913 non-disease-causing SAVs (1,292 in pleiotropic proteins and 3,621 in non-pleiotropic proteins). Pleiotropic proteins had a ratio of "disease-causing" to "non-disease-causing" SAVs almost double that of non-pleiotropic proteins (4.7 vs. 2.5). Moreover, deleterious SAVs were more likely to occur in pleiotropic proteins compared with non-pleiotropic proteins (OR 2.74, P < 0.001). Surprisingly, SAVs annotated as non-disease-causing in the Humsavar database, were also more likely to occur in pleiotropic than non-pleiotropic proteins (OR 1.46, P < 0.001). We, therefore, examined the distribution of common SAVs (MAF ࣙ 0.01) identified through exome sequencing studies in 60,706 unrelated individuals and reported in the EXAC database. We found that common SAVs were significantly less likely to be in pleiotropic compared with non-pleiotropic proteins (OR 0.73, P < 0.001; Table 1 and Supp. Tables S4A and  S4B ). This raised the hypothesis that MAF is an effect modifier for non-disease-causing SAVs distribution. When MAF was taken into account, common variants reported in Humsavar (356 SAVs in pleiotropic and 1,650 in non-pleiotropic) were less likely to be found in pleiotropic proteins (OR 0.88, P < 0.03, although this was just a trend when the larger dataset of 412 pleiotropic proteins was analyzed), whereas rare SAVs (320 SAVs in pleiotropic and 917 in non-pleiotropic) were more likely to be found in pleiotropic proteins (OR 1.43, P < 0.001). For the remaining 1,670 non-disease-causing SAVs reported in Humsavar (616 in pleiotropic and 1,054 in nonpleiotropic proteins), no MAF data were available. These SAVs were more likely to be found in pleiotropic rather than non-pleiotropic proteins (OR 2.40, P < 0.001). As these rare variants and SAVs with no MAF show a distribution similar to that of disease-causing SAVs, this raises the question of whether many of these variants are actually mildly damaging.
Ordered versus Disordered Protein Structure
Significantly more pleiotropic (132 proteins, 51.4%) than nonpleiotropic proteins (516 proteins, 38.4%) contained at least one intrinsically long disordered region of over 50 residues in length (P < 0.001, χ 2 test). This difference was maintained even when lowering our cut-off to define a long intrinsically disordered region from 50 to 30 residues, and when utilizing the disorder prediction program DISOPRED3 (Supp. Table S5 ).
Distribution of SAVs in Relation to Protein Disorder and Pleiotropy
We examined the distribution of disease-causing and nondisease-causing SAVs in ordered and disordered regions of pleiotropic and non-pleiotropic proteins (results for the 412 pleiotropic dataset are presented in Supp. Table S6 ) and found that deleterious SAVs were more likely to occur in ordered rather than disordered regions in both pleiotropic (OR 1.71, P < 0.001) and non-pleiotropic proteins (OR 3.51, P < 0.001). Nevertheless the OR for a deleterious SAV occurring in a disordered region was significantly greater for pleiotropic compared with non-pleiotropic proteins (pleiotropic proteins OR 0.58, 95%C.I. 0.54-0.63, P < 0.001; non-pleiotropic OR 0.29, 95%C.I. 0.26-0.31, P < 0.001; z score for the difference between ORs 11.6, P < 0.001). Common variants from EXAC were similarly more likely to occur in a disordered rather than an ordered region, in both pleiotropic (OR 1.55, P < 0.001) and non-pleiotropic proteins (OR 1.32, P < 0.001; z score for difference between ORs 1.47, P = 0.07). When examining common SAVs reported in the Humsavar database, we confirmed that these are more likely to occur in disordered rather than ordered regions, although this was just a trend for pleiotropic proteins (non-pleiotropic proteins OR 1.29, P < 0.001, pleiotropic proteins OR 1.22, P = 0.11). The lack of statistical significance in the pleiotropic set is likely to be due to the small number of common SAVs analyzed (80 in disordered and 276 in ordered regions). When rare variants were examined, their location was not influenced by the absence of a fixed tertiary structure, neither in pleiotropic (ordered vs. disordered regions: OR 0.80, P = 0.09) or in non-pleiotropic proteins (OR 0.96, P = 0.63). Finally a very weak correlation was found between the length of the disordered protein sequence and the degree of pleiotropism, defined as the number of different disorders caused by the same protein (r = 0.14, P = 0.02).
Pleiotropic and Non-Pleiotropic Proteins Cause Different Classes of Diseases
We examined the distribution of diseases caused by pleiotropic and non-pleiotropic proteins. Congenital malformations, neoplasms, circulatory, and neurological diseases were significantly (P < 0.01) more likely to be caused by pleiotropic rather than nonpleiotropic proteins, whereas the reverse was true for endocrine, metabolic, blood, and immune disorders (Fig. 3 ).
Pleiotropy and Biological Pathways
We mapped 986 out of 1,602 pleiotropic and non-pleiotropic proteins in our dataset on pathways annotated in Reactome. Although the majority of proteins were mapped to only one (602 proteins) or two pathways (238 proteins), a significantly greater number of pleiotropic proteins shared multiple (>2) pathways compared with non-pleiotropic proteins (χ 2 test P < 0.001; Fig. 4 ). Moreover, there was an enrichment of pleiotropic proteins in "signal transduction", "developmental biology", "muscle contraction", "extracellular matrix organization", "membrane trafficking", "binding and uptake of ligands by scavenger receptors" and "hemostasis" pathways, whereas enrichment in non-pleiotropic proteins was found in the "metabolic pathway." When GO terms were examined, pleiotropic proteins were mainly annotated as involved in "cell aggregation", "receptor regulatory activity" and "collagen formation."
Case Studies: Vinculin and Homeobox Pleiotropic Proteins
The following case studies exemplify how protein structural analysis can aid in the identification of the molecular mechanisms underlying the pleiotropic effect of proteins.
Vinculin (VCL, UniProt ID: P18206, HGNC:12665), a binding protein involved in cell-matrix and cell-cell adhesion, is a key component of heart and brain development [Borgon et al., 2004; Carisey and Ballestrem 2011] . It is characterized by the presence of two main domains, vinculin's head (Vh) and vinculin's tail (Vt), which can form intermolecular interactions. In its inactive conformation, most of vinculin's binding sites are hidden and not available for protein-protein interaction [Ziegler et al., 2006] . In the activated state, Vh and Vt domains interact with different proteins: the Vh domain interacts with talin, α-catenin, and α-actinin and the Vt domain interacts with actin, paxillin, and phosphatidylinositol (4,5)-biphosphate (PIP 2 ) [Borgon et al., 2004; Carisey and Ballestrem 2011] . Two diseases have been associated with Vinculin mutations: dilated cardiomyopathy (MIM# 611407), which is caused by p.L954del and p.R975W, and familial hypertrophic cardiomyopathy (MIM# 613255), which is caused by p.L277M. We analyzed the structure of vinculin and showed that residues L954 and R975 are located in the Vt domain. In particular, R975 is part of a positively charged patch on the surface of vinculin and of its alternative spliced form metavinculin and is likely to represent an interaction site. We predict that the R to W substitution alters this charged patch (Fig. 5,  panel A) , thus affecting protein-protein interaction. This hypothesis is supported by in vitro experiments, which demonstrate that p.R975W results in a lack of interaction between vinculin and actin [Olson et al., 2002] . Moreover, R975W could also disrupt an intrachain interaction between R975 and D505, as previously proposed [Rangarajan et al., 2010] . Residue L227 is part of the Vh domain and its substitution with methionine has been described in patients with hypertrophic cardiomyopathy [Vasile et al., 2006] . This residue is partially buried and is part of an alpha helix. Although replacement with M is predicted to have a minimal effect on the overall structure of vinculin, the occurrence of a steric clash with the neighbor F212, cannot be excluded.
The homeobox protein (OTX2, UniProt ID: P32243, HGNC:8522) is a transcription factor which plays a crucial role in eye and visual cortex development [Beby and Lamonerie 2013] . Two diseases are associated with mutations on this protein: severe ocular malformations (MIM# 610125) caused by p.R89G and p.R90S [Ragge et al., 2005] , and anterior pituitary hypoplasia with multiple hormone deficiency (MIM# 613986), caused by p.N225S [Diaczok et al., 2008] . The homeobox protein is characterized by two domains: the Homeobox (Homeobox) and the TF-Otx domain (Fig.  5, panel B) . The Homeobox domain is formed by three alpha helices and interacts with DNA. In particular, the side chains of amino acids located on one of these helices, called recognition helices, make extensive interactions with the DNA major groove. Invariant residues R89 and R90 are part of the recognition helix [Billeter et al., 1993] and their substitution is likely to disrupt the formation of the protein-DNA complex. Residue N225 is located in the TF-Otx domain, thus outside the DNA binding domain. Its substitution with Serine has been shown in vitro to result in a mutant homeobox protein that can still bind to target genes but has a dominant negative inhibitory effect on HESX1 gene expression [Diaczok et al., 2008] , resulting in abnormal development of the anterior pituitary and, hence, deficiency of all pituitary hormones.
In both these case studies, SAVs in different domains resulted in different diseases, which is in agreement with a previous report that mutation pairs on different protein interacting domains are more likely to cause different disorders than those on the same protein interacting domain [Wang et al., 2012] .
Discussion
Pleiotropic proteins are emerging as important contributors to human disease. We demonstrated that pleiotropic proteins are enriched in deleterious SAVs and rare genetic variations and contribute more than non-pleiotropic proteins to certain classes of diseases, such as neoplasias, neurological, and congenital disorders.
We analyzed proteins causing human disease annotated in the UniProt database and showed that 12% of protein-coding genes harboring deleterious SAVs are pleiotropic. Since we used a stringent criterion to define pleiotropy and only considered protein-coding genes harboring amino acid substitutions, it is likely that pleiotropy is an even more widespread phenomenon. A recent systematic review of genetic variations associated with common diseases demonstrated that 17% of genes identified by GWAS are responsible for multiple phenotypes [Sivakumaran et al., 2011] . Pleiotropy poses a formidable challenge when analyzing GWAS data for assessing the dependent or independent association between two phenotypes, or when comparing the enrichment in deleterious variants between patients and controls for establishing the pathogenicity of a gene in relation to a specific phenotype. Identification and characterization of pleiotropic genes and their genetic variations is, therefore, of paramount importance.
In our study, proteins in the pleiotropic and non-pleiotropic datasets differed in terms of their biological properties, with Electrostatic map shows the presence of a large positively charged patch on the surface of Vt domain (the electrostatic potential was calculated using PBEQ (Jo et al. 2008) program, which computes the protein electrostatic potential by solving the Poisson-Boltzmann equation). Panel B: Homeobox protein (OTX2). The homeobox domain alpha helices on OTX2 are presented in green. Residues R89 and R90 are presented in blue. DNA is presented in purple. Protein structures were visualised using the Pymol visualization program (http://www.pymol.org/). enrichment in essential proteins and a higher number of protein interactors in the pleiotropic compared with the non-pleiotropic dataset. This is consistent with previous studies in humans and yeast [Chavali et al., 2010] and supports the hypothesis that pleiotropic proteins have a tendency to have a different biological role compared with non-pleiotropic proteins. Studies in Caenorhabditis elegans have shown that pleiotropic proteins have an important role in early embryological life and potentially bridge different protein pathways [Zou et al., 2008] . Enrichment in essential proteins in our pleiotropic dataset suggests that pleiotropic proteins could also play a similar role in human embryonic life.
Our analysis demonstrated an enrichment in pleiotropic proteins in neoplasias, neurological, circulatory, and congenital disorders, which are among the leading causes of morbidity and mortality in developed countries [Muka et al., 2015] . Conversely, endocrine and metabolic disorders were most commonly caused by non-pleiotropic proteins. These results are in agreement with the human disease network developed by Goh et al. (2007) , which shows that the degree of shared genetic background is not similar for all diseases, but is high for neoplasias and low for endocrine related disorders. Consistent with our results are recent reports of a genetic association between lung and other cancer types from the PAGE and TRICL consortia [Park et al., 2014] and between colorectal cancer and other cancers from the PAGE and GECCO and CCFR consortia [Cheng et al., 2014] . In the case of neurological disorders, there is clinical and genetic evidence of an overlap between conditions, such as frontotemporal dementia and amyotrophic lateral sclerosis (ALS) [Lillo and Hodges 2009; Geser et al., 2010] or ALS, bone dysfunction, and myopathy [Guerreiro et al., 2014] , whereas there is an inverse association between neurological disorders, such as Parkinson and Alzheimer, and the incidence of cancer [Driver 2014 ] in the elderly. Moreover, there is increasing evidence of a shared genetic background between embryological development and cancer [Becker et al., 2012] and evidence of an association between congenital malformations and an increased risk of cancer, especially in young children [Bjørge et al., 2008; Sun et al., 2014] . Although additional studies are needed to clarify the biological mechanisms behind the enrichment of pleiotropic proteins in particular classes of diseases, our findings can help identify a subset of candidate genes for GWAS and exome sequencing studies in cancer and circulatory and neurological disorders.
GWAS have shown that the metabolic syndrome as well as immune-mediated disorders [Sivakumaran et al., 2011; Kraja et al., 2014] are associated with pleiotropic genes, which appears to contradict our results. Two important aspects are worth noticing: firstly, in our study, pleiotropic genes were identified by analyzing disease phenotypes caused by rare variants in coding regions, resulting in amino acid substitutions. On the contrary, GWAS identify pleiotropic genes by analyzing phenotypes associated with common variants, often located in the non-coding region and affecting gene expression or methylation [Gratten and Visscher 2016] . A comprehensive study looking at phenotypes associated with rare and common variants is likely to result in a higher number of pleiotropic genes associated with disease compared with our method. Secondly, the disease classification used in our study differs from that used in the above-cited GWAS [Sivakumaran et al., 2011; Kraja et al., 2014] . The metabolic syndrome is characterized by several biochemical and clinical conditions [Kaur 2014 ] many of which, such as hypertension, a hypercoagulable state, chronic inflammation, and chronic stress are not classified as "endocrine and metabolic disorders" in the ICD-10. We adhered to the ICD-10 classification and chose not to manually define new classes (e.g., for the metabolic syndrome). Moreover, we treated endocrine and metabolic disorders as a single class. Similarly, we chose not to manually merge all immune-mediated disorders into a new class. For this reason, conditions such as type I diabetes or Crohn disease are classified in our study as "metabolic" and "gastrointestinal," respectively, as was the case in other studies [Goh et al., 2007] , whereas these are classified as "immune-mediated conditions" in GWAS analyses linking pleiotropism to immune disorders [Sivakumaran et al., 2011] .
We showed that pleiotropic proteins share multiple pathways. This can-at least in part-explain how different genetic variants in the same pleiotropic protein-coding gene can affect several phenotypic traits and result in similar or opposite disease risks for different disorders. Moreover, we demonstrated an enrichment of pleiotropic proteins in a broad range of core biological pathways, such as signal transduction, developmental biology, and extracellular matrix organization, which is in agreement with the enrichment of pleiotropic proteins in diseases, such as neoplasias and congenital disorders. Although our findings could be the result of a better characterization of pleiotropic proteins compared with non-pleiotropic proteins, it is noteworthy that genes involved in signaling pathways, such as the Notch signaling pathway, are involved in embryogenesis, cancer [Reichrath and Reichrath 2012] , cardiovascular [Rusanescu et al., 2008] , and neurological disorders [Lathia et al., 2008] .
In our dataset, disease-causing SAVs and rare variants were enriched in pleiotropic proteins, whereas common variants were more likely to be found in non-pleiotropic proteins. This suggests that pleiotropic proteins are less likely to tolerate genetic variations and questions arise on the nature-neutral, moderately deleterious, or disease-risk protective-of rare variants observed in these proteins. This becomes particularly important when interpreting the pathogenicity of different genetic variants harbored by the same gene in patients and controls sequenced as part of individual projects or large sequencing efforts, such as the 100K Genomes project.
Although deleterious SAVs were enriched in structurally ordered regions, deleterious variants occurring in structurally disordered regions were more likely to be in a pleiotropic rather than nonpleiotropic protein. Disordered proteins play an important role in cell biology, as they participate in signaling, regulation process, DNA-protein, and protein-protein interaction [Xie et al., 2007] [ Tompa 2005] . The lack of a fixed 3D structure allows disordered regions to assume different conformations, thus, having the ability to interact with multiple partners [Haynes et al., 2006] [Dunker et al., 2005] . The evidence that structure disorder is a common feature in hub proteins (proteins with multiple interactors) [Haynes et al., 2006] prompted us to evaluate its role in the distribution of deleterious SAVs in pleiotropic and non-pleiotropic proteins. Moreover, protein disorder has recently been recognized as an important contributor to disease Vacic et al., 2012) and there is evidence that disordered proteins are associated with cancer [Iakoucheva et al., 2002] and neurological disorders, such as Alzheimer and Parkinson disease [Uversky 2008 ]. Interestingly, the deleterious effect of SAVs occurring in disordered regions is underestimated by variant prediction programs, such as SIFT [Mort et al., 2010] , possibly because of the low sequence conservation, which characterizes these regions [Vacic et al., 2012] . Our results suggest that knowledge of the nature of a protein-pleiotropic versus non-pleiotropic-and of the protein 3D structure-ordered or disordered-could help establish the benign or deleterious nature of a genetic variant. The presence of a genetic variant in a long disordered region of a pleiotropic protein should, in fact, prompt investigation of the effect of such a variant using additional methods, such as ordered-to-disordered transition upon amino acid change [Vacic et al., 2012] .
One important potential limitation of our study is that pleiotropic proteins are likely to be better characterised compared with nonpleiotropic proteins, thus potentially biasing some of our findings, such as the higher number of protein interactors in the pleiotropic set. Nevertheless, other results, such as protein essentiality and protein disorder, are less likely to be biased in favor of extensively characterized proteins and build a consistent picture that supports the hypothesis that pleiotropic proteins are biologically different from non-pleiotropic proteins.
Conclusions
This study provides a better understanding of pleiotropic proteins and their genetic variants, which could greatly aid in the analysis of genetic studies and drug design. In particular, this study provides evidence that pleiotropic proteins are enriched in deleterious SAVs and rare variants and significantly contribute to cancer, neurological, circulatory, and congenital disorders. This emphasizes the importance of acknowledging the phenomenon of pleiotropy when establishing the contribution of genetic variants to human health. The results of this study can guide the selection of candidate genes for classes of disorders enriched in pleiotropic proteins.
